Averion Expands Operations to Europe and Names John Shillingford, PhD as President of New Wholly-Owned Subsidiary Averion GmbH
May 23, 2006, Framingham, Massachusetts, USA- Averion Inc. announced today its expansion into Europe through the creation of Averion GmbH, a new wholly-owned subsidiary based in Germany. The Company also announced the appointment of John Shillingford, PhD as President of Averion GmbH.
Averion GmbH will work to develop relationships with European clients as well as run European studies for existing North American clients. The new subsidiary will offer Averion?s full range of services including: Auditing, Biometrics, Clinical Monitoring, Clinical Project Management, Compliance and Validation, Database Development, Data Management, Data Monitoring and Clinical Endpoint Committees, Medical Monitoring, Medical Writing, Metrics Consulting, Pharmacovigilance, Program Planning/Study Design and Regulatory Consulting.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.